640 related articles for article (PubMed ID: 18327411)
1. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
2. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
3. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
[TBL] [Abstract][Full Text] [Related]
4. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
Kondo N; Wakayama F; Suzuki Y; Fukui K; Takaya S; Fukuda I
Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
[TBL] [Abstract][Full Text] [Related]
5. Combined blockade of ADP receptors and PI3-kinase p110β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation.
Krajewski S; Kurz J; Geisler T; Peter K; Wendel HP; Straub A
PLoS One; 2012; 7(6):e38455. PubMed ID: 22701645
[TBL] [Abstract][Full Text] [Related]
6. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
7. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
8. Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia.
Krajewski S; Kurz J; Neumann B; Greiner TO; Stolz A; Balkau B; Peter K; Unertl K; Wendel HP; Straub A
Br J Anaesth; 2012 Jun; 108(6):912-21. PubMed ID: 22369765
[TBL] [Abstract][Full Text] [Related]
9. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
10. Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model.
Kondo N; Suzuki Y; Wakayama F; Tamai Y; Ji K; Fukui K; Fukuda I
Ann Thorac Surg; 2005 Jul; 80(1):251-7. PubMed ID: 15975376
[TBL] [Abstract][Full Text] [Related]
11. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
12. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Xiao Z; Théroux P; Frojmovic M
Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
[TBL] [Abstract][Full Text] [Related]
13. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
14. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Goto S; Tamura N; Ishida H; Ruggeri ZM
J Am Coll Cardiol; 2006 Jan; 47(1):155-62. PubMed ID: 16386680
[TBL] [Abstract][Full Text] [Related]
15. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
Chiang TM; Zhu J
Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
[TBL] [Abstract][Full Text] [Related]
16. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
[TBL] [Abstract][Full Text] [Related]
17. Delayed inhibition of agonist-induced granulocyte-platelet aggregation after low-dose sevoflurane inhalation in humans.
Wacker J; Lucchinetti E; Jamnicki M; Aguirre J; Härter L; Keel M; Zaugg M
Anesth Analg; 2008 Jun; 106(6):1749-58. PubMed ID: 18499605
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
Schmitt-Sody M; Metz P; Gottschalk O; Zysk S; Birkenmaier C; Goebl M; von Schulze Pellengahr C; Veihelmann A; Jansson V
Inflamm Res; 2007 Oct; 56(10):414-20. PubMed ID: 18026698
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
Kanemitsu S; Nishikawa M; Onoda K; Shimono T; Shimpo H; Yazaki A; Tanaka K; Shiku H; Yada I
J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
[TBL] [Abstract][Full Text] [Related]
20. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways.
Garcia A; Kim S; Bhavaraju K; Schoenwaelder SM; Kunapuli SP
Biochem J; 2010 Jul; 429(2):369-77. PubMed ID: 20441566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
